Harvard University still holds a patent for any animal genetically engineered to develop cancer after an appeal against its patent broke up without conclusion last week. Some anti-patent campaigners now predict that Harvard will emerge from the appeal with a restricted patent, for an "onco-rodent".
The appeal was held by the European patent office after objections to Harvard's patent from campaigners across Europe. The appeal will continue in writing.
请先注册再继续
为何要注册?
- 注册是免费的,而且十分便捷
- 注册成功后,您每月可免费阅读3篇文章
- 订阅我们的邮件
已经注册或者是已订阅?
Please or to read this article.